Fosamax is a non-hormonal medication that has been tested in several clinical studies with a total of 17,000 participants. This drug finds use in anti-osteoporosis therapies due to its ability to render osteoclasts less active, which allows the user to decrease the rapidity of post-menopause bone loss and boost the total osseous mass in most patients. To date, Fosamax stands as the exclusive aid in bone loss management, approved and well-researched by the FDA, that diminishes the occurrence of vertebral and coxal fractures.

The organization approved a daily use of the medicine (10 mg tablets) in 1995, after which certain studies followed aimed at establishing the viability of 70 mg/week single Fosamax applications. Since the year 1997, this pharmaceutical product has been available for 5 mg daily administration in preventive procedures meant to alleviate the condition in female users at over-the-normal risk for the disorder.

The following is characteristic for Fosamax:

  • The drug is sold in a more available generic form;
  • It aims at lowering the risk of you getting an osteoporosis-related fracture (whole-body effect);
  • The dosing schedule can be varied from daily to weekly or twice weekly as appropriate;
  • Released as a regular pill, an oral suspension, or effervescent tablet.

Fosamax vs. Evista: pharmacological properties of raloxifene

Difference between Fosamax and EvistaEvista, similarly, is a SERM that does not contain hormonal agents. It binds to the receptor of estrogen and blocks the skeletal and cardiovascular estrogen action. It also provides antagonistic effects towards estrogen function in the intrauterine and breast tissue. This medicine is diverse in its pharmacodynamics thanks to its biochemical selectivity and many-sided interactivity with the estrogen receptor.

As opposed to other existing anti-osteoporosis therapies, Evista impacts the bone mineral density parameter only mildly, leading to similar benefits in the cases of vertebral breakages, but virtually not impacting the incidence of non-vertebral breakages. The recommendations for this drug cover the categories of osteoporosis sufferers who do not face an excessive risk of osseous fractures and did not have venous thromboembolism in the past.

Distinctions of Evista are as follows:

  • Use of the drug is associated with a diminished risk of estrogen-related cancer;
  • Bone conditions can be further improved with a simultaneous use of calcium and calciferol;
  • It positively influences the levels of total cholesterol and LDL.

Evista vs Fosamax comparison Difference between Fosamax and Evista in numbers

The two medicines offer different approaches to the same issue and are, usually, variably favored from individual to individual. During a 12 month comparative trial, participants in the alendronate cohort demonstrated a greater enhancement in BMD than raloxifene users did at both hip and lumbar spine sites.

The spine and total hip BMD grew by 4.8% and 2.3% with alendronate vs. 2.2% and 0.8% with raloxifene, respectively. Furthermore, this Evista vs Fosamax comparison investigation showed a more pronounced bone turnover for the latter. Overall tolerability was equal. However, the number of participants complaining about vasomotor symptoms was almost three times higher with raloxifene (9.5% vs. 3.7% for alendronate).